Could a simple dose change make a tough cancer drug easier to take?
NCT ID NCT05263050
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II trial is testing whether a different dosing schedule of the drug cabozantinib can reduce side effects while still controlling cancer growth. It includes people with advanced kidney cancer (clear cell or non-clear cell) and neuroendocrine tumors (including carcinoid). Some participants will also receive the immunotherapy nivolumab. The goal is to find a dose that patients can tolerate better, without losing effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cabozantinib (a targeted cancer drug) and nivolumab (an immunotherapy)
What this could lead to
If successful, this could lead to a better-tolerated dosing schedule for cabozantinib, potentially improving quality of life and treatment outcomes for people with advanced kidney cancer or neuroendocrine tumors.
What could go wrong
This is a mid-stage (Phase II) trial with only 111 participants, so results may not apply to everyone. The new dosing might not reduce side effects or improve survival as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••